ATE390922T1 - 2-aminobenzothiazole als cb1 rezeptor inverse agonisten - Google Patents
2-aminobenzothiazole als cb1 rezeptor inverse agonistenInfo
- Publication number
- ATE390922T1 ATE390922T1 AT04739840T AT04739840T ATE390922T1 AT E390922 T1 ATE390922 T1 AT E390922T1 AT 04739840 T AT04739840 T AT 04739840T AT 04739840 T AT04739840 T AT 04739840T AT E390922 T1 ATE390922 T1 AT E390922T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- aminobenzothiazole
- inverse agonist
- receptor inverse
- receptor
- Prior art date
Links
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 title 1
- 239000002469 receptor inverse agonist Substances 0.000 title 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03013403 | 2003-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE390922T1 true ATE390922T1 (de) | 2008-04-15 |
Family
ID=33522251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04739840T ATE390922T1 (de) | 2003-06-20 | 2004-06-11 | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7297707B2 (de) |
| EP (1) | EP1638556B1 (de) |
| JP (1) | JP2007506654A (de) |
| KR (1) | KR100809201B1 (de) |
| CN (1) | CN100368407C (de) |
| AT (1) | ATE390922T1 (de) |
| AU (1) | AU2004251002B2 (de) |
| BR (1) | BRPI0411699A (de) |
| CA (1) | CA2528785A1 (de) |
| DE (1) | DE602004012858T2 (de) |
| ES (1) | ES2303077T3 (de) |
| MX (1) | MXPA05013733A (de) |
| RU (1) | RU2344132C2 (de) |
| WO (1) | WO2005000301A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375349T1 (de) | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
| WO2004058145A2 (en) | 2002-12-19 | 2004-07-15 | Merck & Co., Inc. | Substituted amides |
| BRPI0411699A (pt) * | 2003-06-20 | 2006-08-29 | Hoffmannn La Roche Ag F | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos |
| CN1867332A (zh) * | 2003-10-24 | 2006-11-22 | 索尔瓦药物有限公司 | 包含选择性cb1－拮抗剂和脂肪酶抑制剂的肥胖症的联合治疗 |
| AR046132A1 (es) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| FR2974093B1 (fr) | 2011-04-15 | 2015-05-08 | Michelin Soc Tech | Procede de preparation d'un melange maitre d'elastomere et d'une charge inorganique renforcante |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2025212515A1 (en) * | 2024-04-04 | 2025-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Agents for use in the treatment of endoplasmic stress |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940418A (en) * | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
| JP2759228B2 (ja) * | 1992-05-21 | 1998-05-28 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| NZ503491A (en) * | 1997-11-10 | 2002-08-28 | Bristol Myers Squibb Co | 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors |
| IL141769A0 (en) * | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| PL208098B1 (pl) | 2000-03-23 | 2011-03-31 | Solvay Pharm Bv | Pochodne 4,5-dihydro-1H-pirazolu, kompozycja farmaceutyczna, sposób wytwarzania związków oraz ich zastosowanie |
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| RU2251419C2 (ru) * | 2000-06-21 | 2005-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензотиазола |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| EP1341774B1 (de) * | 2000-12-06 | 2006-02-01 | F. Hoffmann-La Roche Ag | Kondensierte heteroaromatische glucokinaseaktivatoren |
| US6433188B1 (en) * | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
| AU2002317377A1 (en) * | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| US6624163B2 (en) * | 2001-11-29 | 2003-09-23 | Hoffman-La Roche Inc. | Benzothiazole derivatives |
| BRPI0411699A (pt) * | 2003-06-20 | 2006-08-29 | Hoffmannn La Roche Ag F | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos |
-
2004
- 2004-06-11 BR BRPI0411699-2A patent/BRPI0411699A/pt not_active IP Right Cessation
- 2004-06-11 JP JP2006515912A patent/JP2007506654A/ja active Pending
- 2004-06-11 ES ES04739840T patent/ES2303077T3/es not_active Expired - Lifetime
- 2004-06-11 WO PCT/EP2004/006354 patent/WO2005000301A1/en not_active Ceased
- 2004-06-11 EP EP04739840A patent/EP1638556B1/de not_active Expired - Lifetime
- 2004-06-11 DE DE602004012858T patent/DE602004012858T2/de not_active Expired - Lifetime
- 2004-06-11 MX MXPA05013733A patent/MXPA05013733A/es active IP Right Grant
- 2004-06-11 KR KR1020057024471A patent/KR100809201B1/ko not_active Expired - Fee Related
- 2004-06-11 CA CA002528785A patent/CA2528785A1/en not_active Abandoned
- 2004-06-11 CN CNB200480016731XA patent/CN100368407C/zh not_active Expired - Fee Related
- 2004-06-11 AU AU2004251002A patent/AU2004251002B2/en not_active Ceased
- 2004-06-11 AT AT04739840T patent/ATE390922T1/de not_active IP Right Cessation
- 2004-06-11 RU RU2006101458/04A patent/RU2344132C2/ru not_active IP Right Cessation
- 2004-06-18 US US10/871,952 patent/US7297707B2/en not_active Expired - Fee Related
-
2006
- 2006-09-26 US US11/527,063 patent/US20070021478A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060012031A (ko) | 2006-02-06 |
| ES2303077T3 (es) | 2008-08-01 |
| CN100368407C (zh) | 2008-02-13 |
| WO2005000301A1 (en) | 2005-01-06 |
| CA2528785A1 (en) | 2005-01-06 |
| AU2004251002B2 (en) | 2009-10-29 |
| MXPA05013733A (es) | 2006-03-08 |
| BRPI0411699A (pt) | 2006-08-29 |
| US20040266845A1 (en) | 2004-12-30 |
| KR100809201B1 (ko) | 2008-02-29 |
| EP1638556B1 (de) | 2008-04-02 |
| RU2006101458A (ru) | 2007-07-27 |
| AU2004251002A1 (en) | 2005-01-06 |
| US20070021478A1 (en) | 2007-01-25 |
| DE602004012858D1 (de) | 2008-05-15 |
| US7297707B2 (en) | 2007-11-20 |
| EP1638556A1 (de) | 2006-03-29 |
| DE602004012858T2 (de) | 2009-05-14 |
| JP2007506654A (ja) | 2007-03-22 |
| CN1805745A (zh) | 2006-07-19 |
| RU2344132C2 (ru) | 2009-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| ATE384058T1 (de) | Thiazolderivate | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| DE60335869D1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| UY27918A1 (es) | Derivados de benzodioxol | |
| EA200500520A1 (ru) | Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов | |
| EA200701357A1 (ru) | Композиции и способы применения модулятора рецептора 5ht | |
| KR101360556B9 (ko) | 글리코피롤레이트 및 베타2 아드레날린 수용체아고니스트의 조합물 | |
| NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
| SE0403006D0 (sv) | New compounds | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| MX2010002938A (es) | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| DE602006017694D1 (de) | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden | |
| CY1110130T1 (el) | Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α. | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| DE602007011434D1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| DK2201002T3 (da) | 5-HT7-receptorantagonister | |
| BR0307903A (pt) | derivados de arilsulfona | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten | |
| MX2007004910A (es) | Nuevos derivados de indol o benzimidazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1638556 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |